Non-Small Cell Lung Cancer (NSCLC)

Lung cancer is the leading cause of cancer death for both men and women in the United States. Non-small Cell Lung Cancer (NSCLC) is an epithelial cancer, that arises from the epithelial cells of the lung of the central bronchi to terminal alveoli. It represents ~85% of all lung cancer diagnoses. Significant efforts have been made over the years and are still ongoing to discover new drugs to treat advanced and metastatic disease. There remains significant unmet need, in particular, at both ends of the disease spectrum for patients with early stage peripheral tumors and for patients with obstructive disease.

Peripheral tumors

There are currently limited options for the treatment of peripheral tumors, which are treated either with percutaneous surgery or thermal ablation technologies, which are associated with significant morbidities. The advent of robotic bronchoscopy is opening new opportunities to diagnose these tumors earlier and treat them in a non-invasive manner. ImPACT is currently being evaluated in preclinical studies for this indication.

Central airway obstruction

Half of patients with obstructive NSCLC are inoperable owing to medical or technical reasons, and there is currently, no satisfactory treatment for them. They have a dramatic decrease in their quality of life and require rapid, effective palliation and airway de-obstruction. ImPACT is currently being evaluated in this indication.

©2020 by Steba Biotech. Proudly created with Wix.com

Steba biotech ©